Length of stay and charges associated with health care-acquired bloodstream infections

Omar M. Al-Rawajfah, Jeanne Beauchamp Hewitt, Frank Stetzer, Jehanzeb Cheema

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Although many studies have examined outcomes of health care-associated bloodstream infections (HCABSIs), population-based estimates of length of stay (LOS) and costs have seldom been reported. Objectives: Our objective was to generate US national estimates of LOS and costs associated with HCABSIs using the 2003 National Inpatient Sample (NIS). Methods: This study utilized a matched case-control design to estimate LOS and costs associated with HCABSIs based on the 2003 (NIS). A special set of ICD-9-CM codes was used to identify cases. A 1:1 matching procedure was used in which HCABSIs in patients were matched with uninfected patients based on age, sex, and admission diagnosis. We performed weighted analysis to construct population estimates and their standard deviations for LOS and total charges. Results: After applying the case finding criteria, 113,436 HCABSI cases were identified. The weighted mean LOS for HCABSIs cases was 16.0 days compared with 5.4 days for the control group (P <.001). The weighted mean total charges for patients with HCABSIs were $85,813 ($110,183 US in 2010) compared with $22,821 ($29,302 US in 2010) for uninfected patients (P <.001). We estimated that, in 2003, HCABSIs potentially cost the US economy nearly $29 billion ($37.24 billion US in 2010). Conclusion: This study estimated the economic burden of HCABSIs on the US national economy. With some modifications, the annually published NIS data could be useful as a national surveillance tool for health care adverse events including HCABSIs.

Original languageEnglish
Pages (from-to)227-232
Number of pages6
JournalAmerican Journal of Infection Control
Volume40
Issue number3
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Cross Infection
Length of Stay
Delivery of Health Care
Infection
Costs and Cost Analysis
Inpatients
International Classification of Diseases
Population
Economics
Control Groups

Keywords

  • Bloodstream infections
  • Charges
  • Extra cost
  • Health care acquired
  • Health care costs
  • Length of stay
  • National Inpatient Sample
  • Nosocomial
  • United States national estimates

ASJC Scopus subject areas

  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • Epidemiology
  • Health Policy

Cite this

Length of stay and charges associated with health care-acquired bloodstream infections. / Al-Rawajfah, Omar M.; Hewitt, Jeanne Beauchamp; Stetzer, Frank; Cheema, Jehanzeb.

In: American Journal of Infection Control, Vol. 40, No. 3, 04.2012, p. 227-232.

Research output: Contribution to journalArticle

Al-Rawajfah, Omar M. ; Hewitt, Jeanne Beauchamp ; Stetzer, Frank ; Cheema, Jehanzeb. / Length of stay and charges associated with health care-acquired bloodstream infections. In: American Journal of Infection Control. 2012 ; Vol. 40, No. 3. pp. 227-232.
@article{dd2e5fdc184241aa9b28377dca24b60f,
title = "Length of stay and charges associated with health care-acquired bloodstream infections",
abstract = "Background: Although many studies have examined outcomes of health care-associated bloodstream infections (HCABSIs), population-based estimates of length of stay (LOS) and costs have seldom been reported. Objectives: Our objective was to generate US national estimates of LOS and costs associated with HCABSIs using the 2003 National Inpatient Sample (NIS). Methods: This study utilized a matched case-control design to estimate LOS and costs associated with HCABSIs based on the 2003 (NIS). A special set of ICD-9-CM codes was used to identify cases. A 1:1 matching procedure was used in which HCABSIs in patients were matched with uninfected patients based on age, sex, and admission diagnosis. We performed weighted analysis to construct population estimates and their standard deviations for LOS and total charges. Results: After applying the case finding criteria, 113,436 HCABSI cases were identified. The weighted mean LOS for HCABSIs cases was 16.0 days compared with 5.4 days for the control group (P <.001). The weighted mean total charges for patients with HCABSIs were $85,813 ($110,183 US in 2010) compared with $22,821 ($29,302 US in 2010) for uninfected patients (P <.001). We estimated that, in 2003, HCABSIs potentially cost the US economy nearly $29 billion ($37.24 billion US in 2010). Conclusion: This study estimated the economic burden of HCABSIs on the US national economy. With some modifications, the annually published NIS data could be useful as a national surveillance tool for health care adverse events including HCABSIs.",
keywords = "Bloodstream infections, Charges, Extra cost, Health care acquired, Health care costs, Length of stay, National Inpatient Sample, Nosocomial, United States national estimates",
author = "Al-Rawajfah, {Omar M.} and Hewitt, {Jeanne Beauchamp} and Frank Stetzer and Jehanzeb Cheema",
year = "2012",
month = "4",
doi = "10.1016/j.ajic.2011.03.014",
language = "English",
volume = "40",
pages = "227--232",
journal = "American Journal of Infection Control",
issn = "0196-6553",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Length of stay and charges associated with health care-acquired bloodstream infections

AU - Al-Rawajfah, Omar M.

AU - Hewitt, Jeanne Beauchamp

AU - Stetzer, Frank

AU - Cheema, Jehanzeb

PY - 2012/4

Y1 - 2012/4

N2 - Background: Although many studies have examined outcomes of health care-associated bloodstream infections (HCABSIs), population-based estimates of length of stay (LOS) and costs have seldom been reported. Objectives: Our objective was to generate US national estimates of LOS and costs associated with HCABSIs using the 2003 National Inpatient Sample (NIS). Methods: This study utilized a matched case-control design to estimate LOS and costs associated with HCABSIs based on the 2003 (NIS). A special set of ICD-9-CM codes was used to identify cases. A 1:1 matching procedure was used in which HCABSIs in patients were matched with uninfected patients based on age, sex, and admission diagnosis. We performed weighted analysis to construct population estimates and their standard deviations for LOS and total charges. Results: After applying the case finding criteria, 113,436 HCABSI cases were identified. The weighted mean LOS for HCABSIs cases was 16.0 days compared with 5.4 days for the control group (P <.001). The weighted mean total charges for patients with HCABSIs were $85,813 ($110,183 US in 2010) compared with $22,821 ($29,302 US in 2010) for uninfected patients (P <.001). We estimated that, in 2003, HCABSIs potentially cost the US economy nearly $29 billion ($37.24 billion US in 2010). Conclusion: This study estimated the economic burden of HCABSIs on the US national economy. With some modifications, the annually published NIS data could be useful as a national surveillance tool for health care adverse events including HCABSIs.

AB - Background: Although many studies have examined outcomes of health care-associated bloodstream infections (HCABSIs), population-based estimates of length of stay (LOS) and costs have seldom been reported. Objectives: Our objective was to generate US national estimates of LOS and costs associated with HCABSIs using the 2003 National Inpatient Sample (NIS). Methods: This study utilized a matched case-control design to estimate LOS and costs associated with HCABSIs based on the 2003 (NIS). A special set of ICD-9-CM codes was used to identify cases. A 1:1 matching procedure was used in which HCABSIs in patients were matched with uninfected patients based on age, sex, and admission diagnosis. We performed weighted analysis to construct population estimates and their standard deviations for LOS and total charges. Results: After applying the case finding criteria, 113,436 HCABSI cases were identified. The weighted mean LOS for HCABSIs cases was 16.0 days compared with 5.4 days for the control group (P <.001). The weighted mean total charges for patients with HCABSIs were $85,813 ($110,183 US in 2010) compared with $22,821 ($29,302 US in 2010) for uninfected patients (P <.001). We estimated that, in 2003, HCABSIs potentially cost the US economy nearly $29 billion ($37.24 billion US in 2010). Conclusion: This study estimated the economic burden of HCABSIs on the US national economy. With some modifications, the annually published NIS data could be useful as a national surveillance tool for health care adverse events including HCABSIs.

KW - Bloodstream infections

KW - Charges

KW - Extra cost

KW - Health care acquired

KW - Health care costs

KW - Length of stay

KW - National Inpatient Sample

KW - Nosocomial

KW - United States national estimates

UR - http://www.scopus.com/inward/record.url?scp=84858798955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858798955&partnerID=8YFLogxK

U2 - 10.1016/j.ajic.2011.03.014

DO - 10.1016/j.ajic.2011.03.014

M3 - Article

VL - 40

SP - 227

EP - 232

JO - American Journal of Infection Control

JF - American Journal of Infection Control

SN - 0196-6553

IS - 3

ER -